Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis

Prostate Cancer and Prostatic Diseases volume 17, pages 132–143 (2014)Cite this article

Subjects

Abstract

Background:

Testosterone replacement therapy (TRT) is a widely accepted form of treatment worldwide for aging men with late-onset hypogonadism syndrome. Urologists have been concerned about the possibility of TRT causing prostate cancer. The aim of this study was to assess the relationship between TRT and prostate cancer.

Methods:

A literature review was performed to identify all published, randomized controlled trials (RCTs) of testosterone treatment for hypogonadism. The search included the MEDLINE, Embase and the Cochrane Controlled Trials Register databases. Fixed-effect model was chosen for homogeneous studies; otherwise, a random-effect model was used. Inconsistency was quantified by using the I2 statistic, which tests the proportion of heterogeneity across studies.

Results:

Results of 22 RCTs involving a total of 2351 patients were analyzed. Eleven RCTs were short-term (<12 months) and 11 were long-term (12–36 months) comparisons of TRT with a placebo; TRT was administered transdermally, orally or by injection. Respective odds ratio (OR) and 95% confidence interval (CI) values for injection, transdermal administration and oral administration of short-term TRT were as follows: prostate cancer: 0.39 (0.06–2.45), 1.10 (0.26–4.65) and no oral; biopsy: 5.28 (0.24–113.87), 2.11 (0.32–13.73) and no oral; and prostate nodule: 1.01 (0.13–7.60), no injection and oral. Respective OR and 95% CI values for injection, transdermal administration and oral administration of long-term TRT were as follows: prostate cancer: 2.09 (0.18–24.73), 3.06 (0.12–76.70) and 0.19 (0.01–4.03); biopsy: 2.09 (0.18–24.73), 3.65 (0.88–15.20) and 0.97 (0.13–7.03); and prostate nodule: 3.13 (0.12–80.68), 1.00 (0.06–16.41) and 0.97 (0.13–7.03). Though for some routes of administration and some end points, the OR associated with testosterone administration were >1 indicating increased risk, none of these reached or even approached statistical significance (all P>0.10), which was consistent with the results of subgroup analyses and sensitivity analysis. Besides, sensitivity analysis indicated that short-term TRT was more likely to increase PSA levels than treatment with placebo (P<0.00001).

Conclusions:

This meta-analysis shows that regardless of the administration method, TRT is the short-term safety and does not promote prostate cancer development or progression but long-term data are warranted with justifiable end points.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Araujo AB, Esche GR, Kupelian V, O’Donnell AB, Travison TG, Williams RE et al. Prevalence of symptomatic testosterone deficiency in men. J Clin Endocrinol Metab 2007; 92: 4241–4247.

    Article  CAS  Google Scholar 

  2. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR . Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724–731.

    Article  CAS  Google Scholar 

  3. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors. J Clin Endocrinol Metab 2008; 93: 2737–2745.

    Article  CAS  Google Scholar 

  4. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol 2009; 55: 121–130.

    Article  Google Scholar 

  5. Morales A, Schulman CC, Tostain J, Wu CW . Testosterone deficiency syndrome (TDS) needs to be named appropriately—the importance of accurate terminology. Eur Urol 2006; 50: 407–409.

    Article  Google Scholar 

  6. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone density in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 2085–2098.

    Article  CAS  Google Scholar 

  7. Morgentaler A . Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006; 50: 935–939.

    Article  CAS  Google Scholar 

  8. Jadad AR . Randomised Controlled Trials. BMJ Publishing Group: London, UK, 1998.

    Google Scholar 

  9. Higgins JPT, Green S (eds). Cochrane handbook for systematic reviews of interventions, v.5.1 [updated March 2011]. Cochrane Collaboration Web site http://www.cochrane-handbook.org/.

  10. DerSimonian R, Laird N . Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7: 177–188.

    Article  CAS  Google Scholar 

  11. Higgins JP, Thompson SG, Deeks JJ, Altman DG . Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.

    Article  Google Scholar 

  12. Tenover JS . Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092–1098.

    CAS  PubMed  Google Scholar 

  13. Holmang S, Marin P, Lindstedt G, Hedelin H . Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate 1993; 23: 99–106.

    Article  CAS  Google Scholar 

  14. Simon D, Charles MA, Lahlou N, Nahoul K, Oppert JM, Gouault-Heilmann M et al. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care 2001; 24: 2149–2151.

    Article  CAS  Google Scholar 

  15. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 2002; 282: E601–E607.

    Article  CAS  Google Scholar 

  16. Harman SM, Blackman MR . The effects of growth hormone and sex steroid on lean body mass, fat mass, muscle strength, cardiovascular endurance and adverse events in healthy elderly women and men. Horm Res 2003; 60: 121–124.

    CAS  PubMed  Google Scholar 

  17. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R . AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003; 88: 2673–2681.

    Article  CAS  Google Scholar 

  18. Kenny AM, Fabregas G, Song C, Biskup B, Bellantonio S . Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sci Med Sci 2004; 591: 75–78.

    Article  Google Scholar 

  19. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism. AMA 2006; 296: 2351–2361.

    Article  CAS  Google Scholar 

  20. Srinivas-Shanker U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95: 639–650.

    Article  Google Scholar 

  21. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109–122.

    Article  CAS  Google Scholar 

  22. Kaufman JM, Miller MG, Garwin JL, Fitzpatrick S, McWhirter C, Brennan JJ . Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med 2011; 8: 2079–2089.

    Article  CAS  Google Scholar 

  23. Sih R, Morlet JE, Kaiser FE, Perry HM, Rd, Patrick P, Ross C . Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661–1667.

    Article  CAS  Google Scholar 

  24. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 1966–1972.

    CAS  PubMed  Google Scholar 

  25. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG . Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001; 565: 266–272.

    Article  Google Scholar 

  26. Wittert GA, Chapman IM, Haren MT, Mackintosh, Coates P, Morley JE . Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low–normal gonadal status. J Gerontol A Biol Sci Med Sci 2003; 587: 618–625.

    Article  Google Scholar 

  27. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89: 503–510.

    Article  CAS  Google Scholar 

  28. Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006; 355: 1647–1659.

    Article  CAS  Google Scholar 

  29. Emmelot-Vonk MH, Verhaar HJJ, Pour HRN, Aleman A, Lock TM, Bosch JL et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men. AMA 2008; 299: 39–52.

    CAS  Google Scholar 

  30. Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010; 7: 3495–3503.

    Article  CAS  Google Scholar 

  31. Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, Maeda Y et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male 2011; 14: 53–58.

    Article  Google Scholar 

  32. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011; 34: 828–837.

    Article  CAS  Google Scholar 

  33. Hildreth KL, Barry DW, Moreau KL, Vande GJ, Meacham RB, Nakamura T et al. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab 2013; 98: 1891–1900.

    Article  CAS  Google Scholar 

  34. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT Study. Eur Urol 2010; 57: 123–131.

    Article  CAS  Google Scholar 

  35. Hsing AW, Reichardt JK, Stanczyk FZ . Hormones and prostate cancer: current perspectives and future directions. Prostate 2002; 52: 213–235.

    Article  CAS  Google Scholar 

  36. Ross RK, Bernstein L, Lobo RA, Henderson BE, Lobo RA, Stanczyk FZ et al. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992; 339: 887–889.

    Article  CAS  Google Scholar 

  37. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997; 94: 3320–3323.

    Article  CAS  Google Scholar 

  38. Morgentaler A, Traish AM . Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009; 55: 310–320.

    Article  Google Scholar 

  39. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl 2006; 27: 135–137.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Financial support for our studies from the Research Fund of Capital Medical Development (No.2009-2069) and from the Urological Backbone Fund of Beijing Municipal Health Bureau (No.2009-3-15) is gratefully acknowledged.

Author information

Authors and Affiliations

  1. Department of Urology, Beijing Tian-Tan Hospital, Capital Medical University, Beijing, China

    Y Cui, H Zong, H Yan & Y Zhang

Authors
  1. Y Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Zong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Zhang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cui, Y., Zong, H., Yan, H. et al. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 17, 132–143 (2014). https://doi.org/10.1038/pcan.2013.60

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2013.60

Keywords

This article is cited by

Search

Advanced search

Quick links